Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update
23 mai 2023 16h01 HE
|
Alpha Tau Medical Ltd.
- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March - - Treated the first patient with advanced inoperable pancreatic cancer in a...
Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University
17 mai 2023 16h30 HE
|
Alpha Tau Medical Ltd.
JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open
11 mai 2023 16h00 HE
|
Alpha Tau Medical Ltd.
The trial demonstrated a 100% Complete Response rate at 12 weeks post treatment and no device-related serious adverse events or systemic toxicity reported in the 10 patients treated in the feasibility...
Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day
03 mai 2023 16h00 HE
|
Alpha Tau Medical Ltd.
JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial
03 avr. 2023 09h10 HE
|
Alpha Tau Medical Ltd.
JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...
Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit
29 mars 2023 16h00 HE
|
Alpha Tau Medical Ltd.
JERUSALEM, March 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...
Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank
12 mars 2023 08h30 HE
|
Alpha Tau Medical Ltd.
JERUSALEM, March 12, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...
Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update
09 mars 2023 16h10 HE
|
Alpha Tau Medical Ltd.
- Opened U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma, which began enrolling patients in March - - Received Health Canada approval to initiate a liver cancer feasibility trial - ...
Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial
08 mars 2023 17h00 HE
|
Alpha Tau Medical Ltd.
-First two US patients with recurrent cutaneous squamous cell carcinoma have been treated at University Cancer Center in Houston, Texas -Up to 86 patients to be enrolled in the U.S., Canada, Europe...
Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem Headquarters
03 mars 2023 08h30 HE
|
Alpha Tau Medical Ltd.
JERUSALEM, March 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...